Does Fosamax Cause Osteonecrosis of the Jaw?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Occupational Exposure Concerns

The legacy of general health and science information has long served as a foundation for public understanding of medical conditions and their management. Within this broad context, discussions on bone health and the use of medications like bisphosphonates have been part of routine health education. As the domain shifts toward mass production environments, the focus narrows to specific occupational exposures that may arise in industrial settings. In such contexts, workers handling pharmaceutical compounds or involved in manufacturing processes may encounter substances linked to adverse health outcomes. This transition from general health awareness to occupational exposure concern requires careful consideration of how workplace conditions can influence risk profiles. The bridge concept here moves from a broad informational heritage to a targeted examination of exposure scenarios in production facilities, where the potential for contact with agents such as Fosamax (alendronate) becomes a relevant occupational health issue. This pivot underscores the need to evaluate how manufacturing practices and worker safety protocols intersect with known health risks, without delving into mechanistic details or citing specific evidence. The focus remains on the shift in perspective from general health literacy to the practical implications of exposure in mass production settings.

Understanding Fosamax and Its Approved Uses

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its primary mechanism involves increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a serious adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ).

What Is Osteonecrosis of the Jaw?

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, often occurring spontaneously or following dental procedures. Clinical presentation typically involves pain, swelling, infection, and delayed healing after tooth extraction or other invasive dental treatments (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition is generally associated with local infection and delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Diagnosis relies on clinical examination and imaging, with a focus on ruling out other causes of jaw necrosis, such as malignancy or radiation therapy.

Mechanisms Linking Fosamax to ONJ

The mechanistic pathways linking Fosamax to ONJ are not fully understood but are believed to involve bisphosphonate-induced suppression of bone turnover. Bisphosphonates inhibit osteoclast activity, reducing bone resorption and remodeling. In the jawbone, which has high turnover rates due to constant mechanical stress and dental function, this suppression can lead to microdamage accumulation and impaired healing (https://pubmed.ncbi.nlm.nih.gov/40345077/). Additionally, bisphosphonates may have anti-angiogenic effects, reducing blood supply to the jawbone, and can alter immune responses, increasing susceptibility to infection. These factors collectively contribute to the development of ONJ, particularly when combined with local trauma, such as tooth extraction, or infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Risk Factors and Clinical Evidence

The risk of ONJ increases with duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups, suggesting that ONJ is a rare event in the general population but may be more common in those with additional risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Causation and FDA Warnings

Regarding causation, the evidence supports a plausible association between Fosamax use and ONJ, particularly in patients with risk factors. The FDA-approved labeling includes a warning for ONJ, stating that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning advises discontinuation of bisphosphonate treatment if severe symptoms develop, and notes that most patients had relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a subset of patients experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The adequacy of warnings regarding Fosamax and ONJ is addressed in the labeling, which includes a specific section on osteonecrosis of the jaw (Section 5.4) in both the Fosamax and Fosamax Plus D labels (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These warnings describe risk factors, the potential for increased risk with longer exposure, and recommendations for dental care. However, the labeling does not provide specific guidance on the optimal duration of use, noting that the optimal duration has not been determined and that for low-risk patients, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Management and Prevention

For affected patients, causation considerations include the timeline between exposure and documented harm. Symptoms can appear within days to months after starting Fosamax, but ONJ often develops after longer-term use, especially in the presence of risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition is generally associated with dental procedures or local infection, which may act as triggers (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Patients who develop ONJ should be managed with conservative measures, including oral antimicrobial rinses, antibiotics, and avoidance of invasive dental procedures. Discontinuation of Fosamax may be considered, but the decision should be made on a case-by-case basis, weighing the benefits of osteoporosis treatment against the risk of ONJ. In summary, Fosamax is associated with an increased risk of osteonecrosis of the jaw, particularly in patients with additional risk factors. The FDA-approved labeling provides warnings and recommendations for risk mitigation, but the condition remains a serious adverse effect that requires careful monitoring and management.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that can increase the risk of osteonecrosis of the jaw (ONJ), especially in patients with additional risk factors such as invasive dental procedures, cancer, or poor oral hygiene. The FDA labeling includes a warning for ONJ, noting that it has been reported in patients taking bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

How does Fosamax cause osteonecrosis of the jaw?

The exact mechanism is not fully understood, but it is believed to involve suppression of bone turnover due to inhibition of osteoclast activity, leading to microdamage accumulation and impaired healing in the jawbone. Anti-angiogenic effects and altered immune responses may also contribute (https://pubmed.ncbi.nlm.nih.gov/40345077/).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction, implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid conditions like periodontal disease, anemia, and infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long does it take for ONJ to develop after starting Fosamax?

Symptoms can appear from one day to several months after starting Fosamax, but ONJ often develops after longer-term use, especially in the presence of risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.